Literature DB >> 15580218

Abnormal production of tumor necrosis factor (TNF) -- alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected].

Elisabetta Cortis1, Fabrizio De Benedetti, Antonella Insalaco, Stefania Cioschi, Flaminia Muratori, Leila E D'Urbano, Alberto G Ugazio.   

Abstract

We report a family with pyogenic sterile arthritis, pyoderna and acne syndrome (PAPA). The proband presented several episodes of sterile pyogenic arthritis and became unresponsive to glucocorticoids. After treatment with the tumor necrosis factor inhibitor etanercept, the disease underwent rapid and sustained clinical remission. Production of tumor necrosis factor-alpha by mononuclear cells of the proband and of the affected relatives was abnormally elevated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15580218     DOI: 10.1016/j.jpeds.2004.08.001

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  27 in total

1.  Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne).

Authors:  Andrew P Demidowich; Alexandra F Freeman; Douglas B Kuhns; Ivona Aksentijevich; John I Gallin; Maria L Turner; Daniel L Kastner; Steven M Holland
Journal:  Arthritis Rheum       Date:  2011-12-12

2.  Mutation of mouse Mayp/Pstpip2 causes a macrophage autoinflammatory disease.

Authors:  Johannes Grosse; Violeta Chitu; Andreas Marquardt; Petra Hanke; Carolin Schmittwolf; Lutz Zeitlmann; Patricia Schropp; Bettina Barth; Philipp Yu; Rainer Paffenholz; Gabriele Stumm; Michael Nehls; E Richard Stanley
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

5.  Inflammation and wound repair.

Authors:  Danny C LeBert; Anna Huttenlocher
Journal:  Semin Immunol       Date:  2014-05-19       Impact factor: 11.130

Review 6.  Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome: differential diagnosis of septic arthritis by regular detection of exceedingly high synovial cell counts.

Authors:  W Löffler; P Lohse; T Weihmayr; W Widenmayer
Journal:  Infection       Date:  2017-03-01       Impact factor: 3.553

7.  Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome.

Authors:  Pragnesh Mistry; Carmelo Carmona-Rivera; Amanda K Ombrello; Patrycja Hoffmann; Nickie L Seto; Anne Jones; Deborah L Stone; Faiza Naz; Philip Carlucci; Stefania Dell'Orso; Gustavo Gutierrez-Cruz; Hong-Wei Sun; Daniel L Kastner; Ivona Aksentijevich; Mariana J Kaplan
Journal:  Ann Rheum Dis       Date:  2018-08-21       Impact factor: 19.103

Review 8.  Autoinflammation: From monogenic syndromes to common skin diseases.

Authors:  Tien V Nguyen; Edward W Cowen; Kieron S Leslie
Journal:  J Am Acad Dermatol       Date:  2013-02-28       Impact factor: 11.527

9.  The inflammasomes in autoinflammatory diseases with skin involvement.

Authors:  Hans-Dietmar Beer; Emmanuel Contassot; Lars E French
Journal:  J Invest Dermatol       Date:  2014-03-06       Impact factor: 8.551

Review 10.  Monogenic autoinflammatory diseases: concept and clinical manifestations.

Authors:  Adriana Almeida de Jesus; Raphaela Goldbach-Mansky
Journal:  Clin Immunol       Date:  2013-04-09       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.